Cargando…

Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation

Multidrug resistant pathogens are a widespread problem in the hospital setting especially on intensive care units (ICU). This study evaluated the susceptibility of clinical isolates of gramnegative extensively drug resistant organisms (XDR), methicillinresistant Staphylococcus aureus (MRSA), and van...

Descripción completa

Detalles Bibliográficos
Autores principales: GÜNTHER, F., KAISER, S.J., FRIES, T., FRANK, U., MUTTERS, N.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore SRL 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753819/
https://www.ncbi.nlm.nih.gov/pubmed/26900333
_version_ 1782415920336994304
author GÜNTHER, F.
KAISER, S.J.
FRIES, T.
FRANK, U.
MUTTERS, N.T.
author_facet GÜNTHER, F.
KAISER, S.J.
FRIES, T.
FRANK, U.
MUTTERS, N.T.
author_sort GÜNTHER, F.
collection PubMed
description Multidrug resistant pathogens are a widespread problem in the hospital setting especially on intensive care units (ICU). This study evaluated the susceptibility of clinical isolates of gramnegative extensively drug resistant organisms (XDR), methicillinresistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) to a proprietary chlorhexidine digluconate (CHG) formulation used in one brand of CHG-impregnated cloths. Ten isolates each of XDR Pseudomonas aeruginosa, XDR Acinetobacter baumannii, XDR Klebsiella pneumoniae, XDR Escherichia coli, MRSA, and vancomycin-resistant Enterococcus faecium from our hospital were tested. All isolates were susceptible to the proprietary CHG formulation (0.5%, 1%, 2%), with 99% to 100% suppression of growth at the earliest time point in time kill assays (1 minute for gram-positive and 15 seconds for gram-negative organisms). Minimum inhibitory concentrations ranged from 1 : 4096 to 1 : 65536 for MRSA, 1 : 1024 to 1 : 2048 for VRE, 1 : 2048 to 1 : 4096 for XDR E. coli, 1 : 512 to 1 : 2048 for XDR A. baumannii, 1 : 512 to 1 : 1024 for XDR P. aeruginosa, and 1 : 512 to 1 : 1024 for XDR K. pneumoniae. Cloths impregnated with this CHG formulation provide effective protection against colonization and infection by many pathogens. This study provides in vitro evidence that the proprietary CHG formulation used in one brand of CHG-impregnated cloths is effective against XDR gram-negative organisms, MRSA, and VRE.
format Online
Article
Text
id pubmed-4753819
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Pacini Editore SRL
record_format MEDLINE/PubMed
spelling pubmed-47538192016-02-19 Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation GÜNTHER, F. KAISER, S.J. FRIES, T. FRANK, U. MUTTERS, N.T. J Prev Med Hyg Original Article Multidrug resistant pathogens are a widespread problem in the hospital setting especially on intensive care units (ICU). This study evaluated the susceptibility of clinical isolates of gramnegative extensively drug resistant organisms (XDR), methicillinresistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) to a proprietary chlorhexidine digluconate (CHG) formulation used in one brand of CHG-impregnated cloths. Ten isolates each of XDR Pseudomonas aeruginosa, XDR Acinetobacter baumannii, XDR Klebsiella pneumoniae, XDR Escherichia coli, MRSA, and vancomycin-resistant Enterococcus faecium from our hospital were tested. All isolates were susceptible to the proprietary CHG formulation (0.5%, 1%, 2%), with 99% to 100% suppression of growth at the earliest time point in time kill assays (1 minute for gram-positive and 15 seconds for gram-negative organisms). Minimum inhibitory concentrations ranged from 1 : 4096 to 1 : 65536 for MRSA, 1 : 1024 to 1 : 2048 for VRE, 1 : 2048 to 1 : 4096 for XDR E. coli, 1 : 512 to 1 : 2048 for XDR A. baumannii, 1 : 512 to 1 : 1024 for XDR P. aeruginosa, and 1 : 512 to 1 : 1024 for XDR K. pneumoniae. Cloths impregnated with this CHG formulation provide effective protection against colonization and infection by many pathogens. This study provides in vitro evidence that the proprietary CHG formulation used in one brand of CHG-impregnated cloths is effective against XDR gram-negative organisms, MRSA, and VRE. Pacini Editore SRL 2015-12 /pmc/articles/PMC4753819/ /pubmed/26900333 Text en © Copyright by Pacini Editore SRL, Pisa, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
GÜNTHER, F.
KAISER, S.J.
FRIES, T.
FRANK, U.
MUTTERS, N.T.
Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
title Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
title_full Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
title_fullStr Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
title_full_unstemmed Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
title_short Susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
title_sort susceptibility of multidrug resistant clinical pathogens to a chlorhexidine formulation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753819/
https://www.ncbi.nlm.nih.gov/pubmed/26900333
work_keys_str_mv AT guntherf susceptibilityofmultidrugresistantclinicalpathogenstoachlorhexidineformulation
AT kaisersj susceptibilityofmultidrugresistantclinicalpathogenstoachlorhexidineformulation
AT friest susceptibilityofmultidrugresistantclinicalpathogenstoachlorhexidineformulation
AT franku susceptibilityofmultidrugresistantclinicalpathogenstoachlorhexidineformulation
AT muttersnt susceptibilityofmultidrugresistantclinicalpathogenstoachlorhexidineformulation